sanofi nasdaq - Search News

Sanofi Q4 2024 sees strong growth in sales, EPS

Sanofi SA (SNY) Q4 2024 Earnings Call Highlights: Strong Sales Growth and Strategic Investments ...

Sanofi SA (SNY) reports robust sales growth driven by Dupixent and vaccines, while planning a significant share buyback to enhance shareholder value.

Hosted on MSN · 16h

Earnings call transcript: Sanofi Q4 2024 sees strong growth in sales, EPS

Sanofi (NASDAQ:SNY) reported robust financial results for the fourth quarter of 2024, driven by significant sales growth and a solid increase in earnings per share (EPS). The company's net sales rose by 10.

Wall Street Journal · 21h

Sanofi Expects Strong Earnings Growth This Year, Plans $5.2 Billion Buyback

The pharmaceutical company forecasts business earnings per share growth at a low double-digit percentage and plans to launch a $5.2 billion share buyback.

2hon MSN

Sanofi stock price target raised to €120 by Leerink Partners

Sanofi (SAN:FP) (NASDAQ: NASDAQ:SNY) saw its price target increased by Leerink Partners from €113.00 to €120.00, while the firm maintained an Outperform rating on the company's shares. Currently ...

10hon MSN

Sanofi upgraded to hold by Deutsche Bank

Deutsche Bank has upgraded Sanofi (NASDAQ:SNY) to hold from sell, citing the company's Q4 earnings report. The investment ...

Sanofi (NASDAQ:SNY) Shares Sold by Geneos Wealth Management Inc.

Geneos Wealth Management Inc. decreased its position in Sanofi (NASDAQ:SNY – Free Report) by 2.1% in the 4th quarter, Holdings Channel.com reports. The fund owned 10,223 shares of the company’s stock ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results

Sanofi Q4 2024 sees strong growth in sales, EPS

Trending now